1.07

1.83% -0.02

After Hours: 1.08 0.01 +0.93%

Tempest Therapeutics Inc (TPST)

Overview News Price History Option Chain Financials Why TPST Down? Discussions Forecast Stock Split

Tempest Therapeutics Inc stock is traded at $1.07, with a volume of 99,527. It is down -1.83% in the last 24 hours and down -15.75% over the past month. Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Previous Close:

$1.09

Open:

$1.07

24h Volume:

99,527

Relative Volume:

0.55

Market Cap:

$17.10M

Revenue:

Net Income/Loss:

$-43.10M

P/E Ratio:

-0.1723

EPS:

-6.2098

Net Cash Flow:

$-26.38M

1W Performance:

-2.73%

1M Performance:

-15.75%

6M Performance:

-24.11%

1Y Performance:

-69.99%

1-Day Range:

$1.04

$1.0993

1-Week Range:

$1.04

$1.1307

52-Week Range:

$1.02

$6.115

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name

Tempest Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

415-798-8589

Address

2000 SIERRA POINT PARKWAY, BRISBANE

Employee

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

TPST's Discussions on Twitter

Compare TPST vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TPST Tempest Therapeutics Inc	1.07	17.74M	0	-43.10M	-26.38M	-6.2098
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-26	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-10-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Feb-08-24	Initiated	Jefferies	Buy

Tempest Therapeutics Inc Stock (TPST) Latest News

Jun 27, 2026

Tempest Therapeutics Registers 2.43 Million Shares for Resale - Moomoo

Jun 27, 2026

Form S-3 Tempest Therapeutics Inc For: 26 June By Investing.com - Investing.com South Africa

Jun 27, 2026

TPST Forecast — Price Target — Prediction for 2027 - TradingView

Jun 27, 2026

Jun 26, 2026

TPST: Selling Stockholders Plan to Offer 2.43 Million Shares - GuruFocus

Jun 26, 2026

Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares from warrants - Stock Titan

Jun 26, 2026

3OS0 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 25, 2026

Price to earnings forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView

Jun 25, 2026

Price to sales forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView

Jun 25, 2026

Enterprise value to revenue forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView

Jun 25, 2026

Price to sales forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView

Jun 25, 2026

Enterprise value to EBITDA forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView

Jun 25, 2026

Tempest Therapeutics, Inc. Actuals & Estimates (NASDAQ:TPST) - TradingView

Jun 25, 2026

Price to earnings forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView

Jun 25, 2026

Enterprise value to EBIT forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView

Jun 25, 2026